STRATEGIC MARKETING INNOVATIONS

Lobbying for TONIX PHARMACEUTICALS · Clinical-stage biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $40,000.00 income · posted Apr 16, 2026

Lobbying activity 2

Defense

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Health Issues

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.